Frexalimab

Frexalimab
Monoclonal antibody
Type	Whole antibody
Target	CD40 ligand
Clinical data
AHFS/Drugs.com	Monograph
License data	US DailyMed: Abelacimab; US FDA: Abelacimab;
Legal status
Legal status	Investigational;
Identifiers
ChemSpider	none;
KEGG	D10821 ;

Frexalimab (SAR441344) is a second-generation monoclonal antibody that inhibits CD40 ligand. It is in development by Sanofi for the treatment of relapsing multiple sclerosis.^[1]^[2]^[3]^[4]^[5]^[6]

References[edit]

^ Carvalho, Thiago (5 July 2023). "Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis". Nature Medicine. 29 (8): 1882–1883. doi:10.1038/d41591-023-00060-4.
^ Niebel, Dennis; de Vos, Luka; Fetter, Tanja; Brägelmann, Christine; Wenzel, Jörg (July 2023). "Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions". American Journal of Clinical Dermatology. 24 (4): 521–540. doi:10.1007/s40257-023-00774-8. PMC 10157137.
^ Ritter, Jacob; Chen, Yidan; Stefanski, Ana-Luisa; Dörner, Thomas (November 2022). "Current and future treatment in primary Sjögren's syndrome – A still challenging development". Joint Bone Spine. 89 (6): 105406. doi:10.1016/j.jbspin.2022.105406.
^ Fadul, Camilo E.; Mao-Draayer, Yang; Ryan, Kathleen A.; Noelle, Randolph J.; Wishart, Heather A.; Channon, Jacqueline Y.; Kasper, Isaac R.; Oliver, Brant; Mielcarz, Daniel W.; Kasper, Lloyd H. (November 2021). "Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis". Neurology - Neuroimmunology Neuroinflammation. 8 (6): e1096. doi:10.1212/NXI.0000000000001096. PMC 8527364.
^ Vial, G.; Gensous, N.; Duffau, P. (October 2021). "L'axe CD40-CD40L : implications actuelles et futures en immunologie clinique". La Revue de Médecine Interne. 42 (10): 722–728. doi:10.1016/j.revmed.2021.02.005.
^ Cree, Bruce A.C.; Hartung, Hans-Peter; Barnett, Michael (June 2022). "New drugs for multiple sclerosis: new treatment algorithms". Current Opinion in Neurology. 35 (3): 262–270. doi:10.1097/WCO.0000000000001063.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[1] Carvalho, Thiago (5 July 2023). "Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis". Nature Medicine. 29 (8): 1882–1883. doi:10.1038/d41591-023-00060-4.

[2] Niebel, Dennis; de Vos, Luka; Fetter, Tanja; Brägelmann, Christine; Wenzel, Jörg (July 2023). "Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions". American Journal of Clinical Dermatology. 24 (4): 521–540. doi:10.1007/s40257-023-00774-8. PMC 10157137.

[3] Ritter, Jacob; Chen, Yidan; Stefanski, Ana-Luisa; Dörner, Thomas (November 2022). "Current and future treatment in primary Sjögren's syndrome – A still challenging development". Joint Bone Spine. 89 (6): 105406. doi:10.1016/j.jbspin.2022.105406.

[4] Fadul, Camilo E.; Mao-Draayer, Yang; Ryan, Kathleen A.; Noelle, Randolph J.; Wishart, Heather A.; Channon, Jacqueline Y.; Kasper, Isaac R.; Oliver, Brant; Mielcarz, Daniel W.; Kasper, Lloyd H. (November 2021). "Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis". Neurology - Neuroimmunology Neuroinflammation. 8 (6): e1096. doi:10.1212/NXI.0000000000001096. PMC 8527364.

[5] Vial, G.; Gensous, N.; Duffau, P. (October 2021). "L'axe CD40-CD40L : implications actuelles et futures en immunologie clinique". La Revue de Médecine Interne. 42 (10): 722–728. doi:10.1016/j.revmed.2021.02.005.

[6] Cree, Bruce A.C.; Hartung, Hans-Peter; Barnett, Michael (June 2022). "New drugs for multiple sclerosis: new treatment algorithms". Current Opinion in Neurology. 35 (3): 262–270. doi:10.1097/WCO.0000000000001063.

[1]

[2]

[3]

[4]

[5]

[6]